Switching Cholesterol Drugs May Be Fatal: Study
A new study backed by Pfizer Inc. suggests that patients switching from Pfizer's cholesterol-lowering drug Lipitor to zimvastin, a generic version of Merck & Co.'s Zocor, are 30% more likely to...To view the full article, register now.
Already a subscriber? Click here to view full article